NIH researchers prevent blindness in animal models of dry AMD

Findings set stage for first clinical trial of stem cell-based therapeutic approach for AMD. Using a novel patient-specific stem cell-based therapy, researchers at the National Eye Institute (NEI) prevented blindness in animal models of geographic atrophy, the advanced “dry” form of age-related macular degeneration (AMD). The protocols established by the animal study* set the stage [Read More]

KSI-301 Joins List of Proposed Longer Lasting Anti-VEGF Drugs

Kodiak Sciences Inc. has announced promising results from their Phase 1 clinical trial of KSI-301, a novel anti-VEGF compound for the treatment of age-related macular degeneration, retinal vein occlusion, and diabetic macular edema. Currently approved anti-VEGF drugs require several monthly “loading dosages” at the beginning of the treatment regimen. Twelve weeks after a single dose [Read More]

Another Step Closer to Eye Drops for Wet AMD

Scientists are one step closer to developing an eye drop that could revolutionize treatment for wet age-related macular degeneration (wAMD). The condition is currently treated by injections of anti-VEGF drugs into the eye. Eye drops have been tested successfully in rats, but scientists have now investigated the effect of eye drops in the larger eyes [Read More]